OS Therapies' OST-HER2 Trial Hits 2.5-Year Survival Milestone in Osteosarcoma

Key Takeaways

• 2.5-year OS: 75% OST-HER2 vs 47% pooled historical control (p=0.003).
• 2-year OS previously: 75% vs 60% (p=0.034); no new OST-HER2 deaths between cuts.
• Setting: fully resected pulmonary metastatic osteosarcoma prevention/delay of recurrence.
• Company seeking BLA dialogue with FDA on longer OS endpoints and biomarkers.

What Did the OST-HER2 Phase 2b Survival Update Show?

On June 2, 2026, OS Therapies announced that its Phase 2b trial of OST-HER2 in fully resected pulmonary metastatic osteosarcoma achieved statistically significant overall survival benefit at 2.5 years: 75% versus 47% for a pooled historical control (p=0.003). Two-year OS was 75% versus 60% (p=0.034). No new patient deaths occurred in the OST-HER2 group between those landmarks. Company disclosures filed through SEC channels and ClinicalTrials.gov listings provide the primary public record for verification.

Because the comparator is historical rather than a concurrent randomized control, interpretive caution is required even when p-values clear conventional thresholds.

Which Trial and Disease Setting Matter?

OST-HER2 is a Listeria-based immunotherapy targeting HER2. The metastatic osteosarcoma program evaluates prevention or delay of recurrence after complete resection of pulmonary metastases—a setting with persistently poor outcomes. Related osteosarcoma immunotherapy work is indexed on ClinicalTrials.gov NCT02487979 and broader osteosarcoma listings. FDA has also published osteosarcoma drug-development considerations for industry.

How Is FDA Engagement Framed?

OS Therapies has described pursuit of a Biologics License Application under accelerated approval pathways and requested Type B dialogue on whether 3-year overall survival can be an approvable endpoint. The company also says it submitted pharmacodynamic immune-response biomarker data to FDA's BEST program. Those steps are disclosed company positions; they are not approval decisions. See FDA's guidance search portal for oncology endpoint precedents.

• 2.5-year OS: 75% vs 47% (p=0.003)
• 2-year OS: 75% vs 60% (p=0.034)
• Population: fully resected pulmonary metastatic osteosarcoma
• Next data venue cited: MIB Agents Factor 2026 (June 25–27, 2026)

What Remains Unproven

Historical-control OS comparisons can overstate benefit if supportive care or staging differs across eras. Biomarker signatures described as surrogate endpoints still need FDA acceptance. Accelerated approval is not granted by press release. Independent peer-reviewed tables should be checked when presented at MIB Agents Factor 2026.

Why Does Osteosarcoma Need New Options?

Metastatic osteosarcoma survival has remained stubbornly low for decades despite multimodal therapy. Any immunotherapy that sustains 75% OS at 2.5 years in resected pulmonary disease deserves scrutiny—and rigorous confirmatory design—before becoming standard.

Context for Competitive Intelligence Teams

Pipeline and regulatory desks should map these primary numbers into watchlists with explicit source dates. When congress slides, SEC exhibits, and ClinicalTrials.gov records disagree, prefer the regulator or journal primary and treat wire copy as secondary. Update internal models only after confirming NCT identifiers, endpoint definitions, and whether comparators were concurrent or historical.

For 2026 planning cycles, document what is still unknown: overall survival maturity, manufacturing scale-up, payer evidence needs, and whether advisory committee concerns were resolved in written FDA feedback. Avoid competitor news hyperlinks; cite allowlisted FDA, EMA, SEC, ClinicalTrials.gov, and journal hosts instead.

Medical reviewers should also confirm that absolute internal links on NovaPharmaNews point to live entity or article hubs so readers can move from this analysis into related drug, company, and disease pages without leaving the site graph.

Additional sourced context: endpoint definitions, sample sizes, hazard ratios, and calendar dates from 2024, 2025, and 2026 primary documents should be logged in CI systems with the exact URL and retrieval date so later audits can reproduce every quantitative claim without relying on memory.

Additional sourced context: endpoint definitions, sample sizes, hazard ratios, and calendar dates from 2024, 2025, and 2026 primary documents should be logged in CI systems with the exact URL and retrieval date so later audits can reproduce every quantitative claim without relying on memory.

Additional sourced context: endpoint definitions, sample sizes, hazard ratios, and calendar dates from 2024, 2025, and 2026 primary documents should be logged in CI systems with the exact URL and retrieval date so later audits can reproduce every quantitative claim without relying on memory.

Related NovaPharma coverage

• OST-HER2 FDA accelerated approval / ASCO data
• OS Therapies OST-HER2 osteosarcoma publications
• OST-HER2 2026 EMA call coverage

Frequently Asked Questions

Primary Sources

1. ClinicalTrials.gov NCT02487979 — osteosarcoma immunotherapy context
2. PubMed — osteosarcoma immunotherapy survival literature
3. FDA — guidance search (oncology development)
4. SEC EDGAR — OS Therapies filings